Ligand Pharmaceuticals, Inc. (LGND)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Ligand Pharmaceuticals, Inc. (LGND)
Company Performance

Current Price

as of Dec 04, 2024

$120.98

P/E Ratio

48.13

Market Cap

$2.29B

Description

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Metrics

Overview

  • HQJupiter, FL
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerLGND
  • Price$120.98+0.88%

Trading Information

  • Market cap$2.29B
  • Float97.68%
  • Average Daily Volume (1m)135,376
  • Average Daily Volume (3m)109,148
  • EPS$2.63

Company

  • Revenue$152.42M
  • Rev growth (1yr)57.64%
  • Net income-$7.17M
  • Gross margin79.33%
  • EBITDA margin39.61%
  • EBITDA$20.52M
  • EV$1.63B
  • EV/Revenue10.70
  • P/E48.13
  • P/S14.62
  • P/B2.70
Documents
SEC Filings
8-K (2024-11-07)
8-K (2024-08-06)
8-K (2024-08-02)
8-K (2024-07-17)
8-K (2024-07-10)
8-K (2024-07-08)
8-K (2024-06-27)
8-K (2024-06-18)
8-K (2024-06-17)
8-K (2024-05-30)
8-K (2024-05-07)
8-K (2024-04-19)
8-K (2024-02-27)
8-K (2024-01-08)
8-K (2023-12-01)
8-K (2023-11-08)
8-K (2023-10-18)
8-K (2023-09-27)
8-K (2023-09-18)
8-K (2023-08-08)
8-K (2023-06-09)
8-K (2023-05-04)
8-K (2023-03-13)
8-K (2023-02-22)
10-Q (2024-11-08)
10-Q (2024-08-07)
10-Q (2024-05-08)
10-Q (2023-11-09)
10-Q (2023-08-09)
10-Q (2023-05-08)
10-K (2024-02-29)
10-K (2023-02-28)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-08)
Earnings Report (2023-08-08)
Factset
Factset Business Description
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Ligand Pharmaceuticals Q3 ($52.23, 0.00) (2023-11-08T22:59:41Z)
Palvella Therapeutics and Ligand Pharmaceuticals expand strategic partnership to accelerate Phase 3 development of QTORIN rapamycin ($58.31, 0.00) (2023-12-01T13:22:15Z)
Ligand Pharmaceuticals reports Q3 EPS $1.02 ex-items vs FactSet $0.62 [5 est, $0.46-0.70] ($51.92, 0.00) (2023-11-08T21:05:00Z)
FDA making progress with complex generics; multiple regulatory updates (2023-11-17T18:33:10Z)
FDA approves sNDA for Bonsity (teriparatide) and removes boxed warning -- (earlier) ($58.14, +1.01) (2023-11-17T18:04:51Z)
Wikipedia
Ligand_Pharmaceuticals,_Inc.